83 FR 12193 - Notice of Closed Meeting
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention Federal Register Volume 83, Issue 54 (March 20, 2018)
Centers for Disease Control and Prevention
Federal Register Volume 83, Issue 54 (March 20, 2018)
| Page Range | 12193-12193 | |
| FR Document | 2018-05577 |
[Federal Register Volume 83, Number 54 (Tuesday, March 20, 2018)] [Notices] [Page 12193] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2018-05577] ======================================================================= ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)--GH18-004, Advancing Public Health in Central America (Belize, Costa Rica, Dominican Republic, El Salvador, Guatemala, Honduras, Nicaragua, Panama). Date: April 17, 2018. Time: 9:00 a.m.-2:00 p.m., EDT. Place: Teleconference. Agenda: To review and evaluate grant applications. For Further Information Contact: Hylan Shoob, Ph.D., Scientific Review Officer, Center for Global Health, CDC, 1600 Clifton Drive, Atlanta, GA 30331, (404) 639-4796; [email protected]. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2018-05577 Filed 3-19-18; 8:45 am] BILLING CODE 4163-18-P
![Federal Register / Vol. 83, No. 54 / Tuesday, March 20, 2018 / Notices 12193
containing a consent order from Nectar would affect compliance with the order. Officer, Center for Global Health, CDC,
Brand LLC, also d/b/a Nectar Sleep; Part IV requires respondent to maintain 1600 Clifton Drive, Atlanta, GA 30331,
Dreamcloud, LLC; and Dreamcloud certain records, including records (404) 639–4796; HShoob@cdc.gov.
Brand LLC (‘‘respondent’’). necessary to demonstrate compliance The Director, Management Analysis
The proposed consent order has been with the order. Part V requires and Services Office, has been delegated
placed on the public record for thirty respondent to submit additional the authority to sign Federal Register
(30) days for receipt of comments by compliance reports when requested by notices pertaining to announcements of
interested persons. Comments received the Commission and to permit the meetings and other committee
during this period will become part of Commission or its representatives to management activities, for both the
the public record. After thirty (30) days, interview respondent’s personnel. Centers for Disease Control and
the Commission will again review the Finally, Part VI is a ‘‘sunset’’ Prevention and the Agency for Toxic
agreement and the comments received, provision, terminating the order after Substances and Disease Registry.
and will decide whether it should twenty (20) years, with certain
withdraw from the agreement or make Elaine L. Baker,
exceptions.
final the agreement’s proposed order. The purpose of this analysis is to aid Director, Management Analysis and Services
This matter involves respondent’s public comment on the proposed order. Office, Centers for Disease Control and
marketing, sale, and distribution of Prevention.
It is not intended to constitute an
mattresses with claims that the products [FR Doc. 2018–05577 Filed 3–19–18; 8:45 am]
official interpretation of the proposed
are assembled in the United States. order or to modify its terms in any way. BILLING CODE 4163–18–P
According to the FTC’s complaint,
By direction of the Commission.
respondent represented that its products
are ‘‘assembled in the USA.’’ In fact, the Donald S. Clark, DEPARTMENT OF HEALTH AND
respondent’s mattresses are wholly Secretary. HUMAN SERVICES
imported. Therefore, this representation [FR Doc. 2018–05613 Filed 3–19–18; 8:45 am]
was false or misleading. Based on the BILLING CODE 6750–01–P
Centers for Disease Control and
foregoing, the complaint alleges that Prevention
respondent engaged in deceptive acts or
Notice of Closed Meeting
practices in violation of Section 5(a) of DEPARTMENT OF HEALTH AND
the FTC Act. HUMAN SERVICES Pursuant to section 10(d) of the
The proposed consent order contains Federal Advisory Committee Act, as
provisions designed to prevent Centers for Disease Control and amended, notice is hereby given of the
respondent from engaging in similar Prevention following meeting.
acts and practices in the future. The meeting will be closed to the
Consistent with the FTC’s Enforcement Notice of Closed Meeting public in accordance with the
Policy Statement on U.S. Origin Claims, Pursuant to section 10(d) of the provisions set forth in sections
Part I prohibits respondent from making Federal Advisory Committee Act, as 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
U.S.-origin claims for their products amended, notice is hereby given of the as amended, and the Determination of
unless either: (1) The final assembly or following meeting. the Director, Management Analysis and
processing of the product occurs in the The meeting will be closed to the Services Office, CDC, pursuant to Public
United States, all significant processing public in accordance with the Law 92–463. The grant applications and
that goes into the product occurs in the provisions set forth in sections the discussions could disclose
United States, and all or virtually all 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., confidential trade secrets or commercial
ingredients or components of the as amended, and the Determination of property such as patentable material,
product are made and sourced in the the Director, Management Analysis and and personal information concerning
United States; (2) a clear and Services Office, CDC, pursuant to Public individuals associated with the grant
conspicuous qualification appears Law 92–463. The grant applications and applications, the disclosure of which
immediately adjacent to the the discussions could disclose would constitute a clearly unwarranted
representation that accurately conveys confidential trade secrets or commercial invasion of personal privacy.
the extent to which the product contains property such as patentable material, Name of Committee: Disease,
foreign parts, ingredients or and personal information concerning Disability, and Injury Prevention and
components, and/or processing; or (3) individuals associated with the grant Control Special Emphasis Panel (SEP)—
for a claim that a product is assembled applications, the disclosure of which GH14–002, Addressing Emerging
in the United States, the product is last would constitute a clearly unwarranted Infectious Diseases in Bangladesh;
substantially transformed in the United invasion of personal privacy. GH16–003, Conducting Public Health
States, the product’s principal assembly Name of Committee: Disease, Research in Thailand: Technical
takes place in the United States, and Disability, and Injury Prevention and collaboration with the Ministry of
United States assembly operations are Control Special Emphasis Panel (SEP)— Public Health in the Kingdom of
substantial. GH18–004, Advancing Public Health in Thailand (MOPH); GH16–006,
Part II prohibits respondent from Central America (Belize, Costa Rica, Conducting Public Health Research in
making any country-of-origin claim Dominican Republic, El Salvador, Kenya; GH17–005, Conducting Public
about a product or service unless the Guatemala, Honduras, Nicaragua, Health Research in China.
claim is true, not misleading, and Panama). Date: April 10, 2018.
daltland on DSKBBV9HB2PROD with NOTICES
respondent has a reasonable basis Date: April 17, 2018. Time: 9:00 a.m.–2:00 p.m., EDT.
substantiating the representation. Time: 9:00 a.m.–2:00 p.m., EDT. Place: Teleconference.
Parts III through V are reporting and Place: Teleconference. Agenda: To review and evaluate grant
compliance provisions. Part III requires Agenda: To review and evaluate grant applications.
the filing of compliance reports within applications. For Further Information Contact:
one year after the order becomes final For Further Information Contact: Hylan Shoob, Ph.D., Scientific Review
and within 14 days of any change that Hylan Shoob, Ph.D., Scientific Review Officer, Center for Global Health, CDC,
VerDate Sep<11>2014 19:08 Mar 19, 2018 Jkt 244001 PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 E:\FR\FM\20MRN1.SGM 20MRN1](https://thefederalregister.org/doc/83_FR_12247/page/1.svg)
Document Created: 2018-03-20 01:10:44
Document Modified: 2018-03-20 01:10:44
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Dates | April 17, 2018. | |
| Contact | Hylan Shoob, Ph.D., Scientific Review Officer, Center for Global Health, CDC, 1600 Clifton Drive, Atlanta, GA 30331, (404) 639-4796; [email protected] | |
| FR Citation | 83 FR 12193 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR